| Schedule of Segment Reporting Information, by Segment |
The following table is a comparative summary of the Company’s net sales and segment profit by reportable segment for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
| |
2021 |
2020 |
|
2021 |
|
2020 |
Segment Net Sales:
|
|
|
|
|
|
|
|
| Cannabinoid |
$ |
901
|
|
|
$ |
1,136 |
|
|
$ |
2,157
|
|
|
$ |
1,531 |
|
| Non-Cannabinoid |
3,130
|
|
|
2,781 |
|
|
9,023
|
|
|
7,239 |
|
| Total net sales |
4,031
|
|
|
3,917 |
|
|
11,180
|
|
|
8,770 |
|
| |
|
|
|
|
|
|
|
Segment Profit (Loss):
|
|
|
|
|
|
|
|
| Cannabinoid |
(4,391) |
|
|
(4,529) |
|
|
(10,859) |
|
|
(14,384) |
|
| Non-Cannabinoid |
551
|
|
|
933 |
|
|
1,797
|
|
|
1,346 |
|
| Total segment loss |
$ |
(3,840) |
|
|
$ |
(3,596) |
|
|
$ |
(9,062) |
|
|
$ |
(13,038) |
|
| |
|
|
|
|
|
|
|
Reconciliation:
|
|
|
|
|
|
|
|
| Total segment loss |
(3,840) |
|
|
(3,596) |
|
|
(9,062) |
|
|
(13,038) |
|
| Unallocated corporate expenses |
(2,243) |
|
|
(92) |
|
|
(8,416) |
|
|
(4,037) |
|
| Non-cash share-based compensation |
(3,264) |
|
|
(489) |
|
|
(8,137) |
|
|
(1,202) |
|
| Depreciation and amortization |
(337) |
|
|
(534) |
|
|
(1,440) |
|
|
(1,251) |
|
|
|
|
|
|
|
|
|
| Goodwill impairment |
—
|
|
|
— |
|
|
—
|
|
|
(1,682) |
|
| Loss from operations |
$ |
(9,684) |
|
|
$ |
(4,711) |
|
|
$ |
(27,055) |
|
|
$ |
(21,210) |
|
| |
|
|
|
|
|
|
|
| Gain on debt extinguishment, net |
(3,375) |
|
|
— |
|
— |
|
(3,375) |
|
|
— |
|
| Loss on fair value of derivative instrument |
—
|
|
|
57 |
|
— |
|
—
|
|
|
57 |
|
| Gain on remeasurement of warrant liability |
(9,065) |
|
|
— |
|
— |
|
(5,390) |
|
|
— |
|
| Loss on investments |
—
|
|
|
58 |
|
— |
|
—
|
|
|
318 |
|
| Foreign exchange loss |
298
|
|
|
96 |
|
— |
|
1,137
|
|
|
455 |
|
| Interest expense |
485
|
|
|
1,204 |
|
— |
|
2,383
|
|
|
2,993 |
|
| Other expense, net |
964
|
|
|
(20) |
|
— |
|
(123) |
|
|
28 |
|
| Gain (loss) before loss from equity investment |
$ |
1,009
|
|
|
$ |
(6,106) |
|
|
$ |
(21,687) |
|
|
$ |
(25,061) |
|
During 2021 and 2020, the Company's net sales for the non-cannabinoid segment were in the U.S.; cannabinoid net sales were mostly outside of the U.S., primarily in Colombia, Israel, Brazil and Australia.
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
2021 |
|
December 31,
2020 |
Long-lived assets
|
|
|
|
| Cannabinoid |
$ |
29,513
|
|
|
$ |
25,485 |
|
Non-Cannabinoid |
136
|
|
|
176 |
|
Other(a)
|
16
|
|
|
19 |
|
| |
$ |
29,665
|
|
|
$ |
25,680 |
|
|
| Disaggregation of Revenue by Channel |
The following table disaggregates the Company’s revenue by channel for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
2021 |
|
2020 |
|
2021 |
|
2020 |
| Mass retail |
$ |
1,958
|
|
|
$ |
2,602 |
|
|
$ |
5,567
|
|
|
$ |
4,635 |
|
| Specialty, health and other retail |
277
|
|
|
97 |
|
|
852
|
|
|
1,007 |
|
| Distributors |
1,650
|
|
|
1,130 |
|
|
4,330
|
|
|
2,705 |
|
| E-commerce |
146
|
|
|
88 |
|
|
431
|
|
|
423 |
|
|
$ |
4,031
|
|
|
$ |
3,917 |
|
|
$ |
11,180
|
|
|
$ |
8,770 |
|
|